ARTICLE SUMMARY:
Micro-invasive glaucoma surgery (MIGS) is one of the hottest device categories in ophthalmology, perhaps even in the entire device industry. In the past year, the field has seen the acquisition of just about all of the first-generation companies, and one second-generation ompany that was at a fairly early stage.
When Glaukos Corp. started out fifteen years ago, its goal was to fill a large gap in treatments for people with glaucoma: to halt a disease process that leads to irreversible blindness.
